DNA Damage Response And Cancer Treatment

Abstract

DNA damage is a double-edged sword in cancer cells. Where DNA Damage response is deficient to undergoing DNA repair in tumor cells ie; deficiencies of DDR proteins, DNA damage response inhibitors drugs act as anticancer effectiveness that have more potent to kill cancer cells. Designing specific inhibitor to targeting in DNA repair pathway. There are several proteins and their inhibitors being developed and under preclinical and clinical trials. Here might be useful in multiple myeloma, lymphoma, proliferative disorder, head and neck squamous cell carcinoma, breast cancer, ovarian clear cell carcinoma, cholangiocarcinoma and high-risk neuroblastoma likely few types of cancer included in this study. This will carry some of evidence and points regarding resistance in chemotherapy and radiotherapy during utilization DDRinhibitors. Finally, we conclude that emerging DDR Inhibitors which are under clinical trial are beneficial and improves therapeutic outcomes.